AIM:
Pharmacologic agents with procoagulant effects and antidotes against antithrombotic drugs play an important role in the prevention and management of perioperative coagulopathic bleeding. Aim of this narrative review is knowledge transfer on new and renewed hemostatic agents to anesthesiologists and other physicians involved in perioperative medicine.
METHODS:
The literature search was performed in PubMed and the Summaries of Product Characteristics of 6 pharmacologic agents of interest: fibrinogen concentrate, vonicog alfa, susoctocog alfa, idarucizumab, andexanet alfa, argatroban.
RESULTS AND DISCUSSION:
This review highlights renewed interest in fibrinogen concentrate, an old prohemostatic drug, in correcting hypofibrinogenemia which is a leading pathomechanism of perioperative bleeding. This review describe clinically relevant aspects for brand new recombinant prohemostatic drugs for their use in critical clinical situations: vonicog alfa for the prevention and correction of bleeding in von Willebrand syndrome, susoctocog alfa in acquired hemophilia A. Clinical experience and increasing evidence broadened the field of applications of the old antithrombotic drug argatroban to heparin resistance. New antidotes against new anthrombotic agents revolutionized safety of chronic antithrombotic therapy in the emergency situations of acute and trauma surgery. Information on dosing and handling of new hemostatic drugs is summarized.
CONCLUSION:
New and potent hemostatic agents exist for perioperative use and may enrich the armamentarium of anesthesiologists. Implementation into clinical practice requires their availability and user knowledge. Sustainability of these new drugs will depend on post-licensing research, cost-effectiveness, and clinical experience.
Curr Pharm Des. 8 luglio 2019: 10.2174 / 1381612825666190708183127. [Epub prima della stampa]
New Hemostatic Agents: Perioperative Anesthetic Considerations
Antonia K, Sibylle K.